202 related articles for article (PubMed ID: 21068404)
1. Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4.
Zhang B; Jia H; Liu J; Yang Z; Jiang T; Tang K; Li D; Huang C; Ma J; Shen GX; Ye D; Huang B
J Immunol; 2010 Dec; 185(12):7199-206. PubMed ID: 21068404
[TBL] [Abstract][Full Text] [Related]
2. Identification of myeloid-derived suppressor cells and T regulatory cells in lung microenvironment after Urethane-induced lung tumor.
Rosin FC; Pedregosa JF; de Almeida JS; Bueno V
Int Immunopharmacol; 2011 Jul; 11(7):873-8. PubMed ID: 21238620
[TBL] [Abstract][Full Text] [Related]
3. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.
Teng MW; Swann JB; von Scheidt B; Sharkey J; Zerafa N; McLaughlin N; Yamaguchi T; Sakaguchi S; Darcy PK; Smyth MJ
Cancer Res; 2010 Apr; 70(7):2665-74. PubMed ID: 20332236
[TBL] [Abstract][Full Text] [Related]
4. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.
Haile LA; Gamrekelashvili J; Manns MP; Korangy F; Greten TF
J Immunol; 2010 Jul; 185(1):203-10. PubMed ID: 20525890
[TBL] [Abstract][Full Text] [Related]
5. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells.
Medina-Echeverz J; Fioravanti J; Zabala M; Ardaiz N; Prieto J; Berraondo P
J Immunol; 2011 Jan; 186(2):807-15. PubMed ID: 21148040
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
[TBL] [Abstract][Full Text] [Related]
7. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
8. 3-Methylcholanthrene-induced transforming growth factor-beta-producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy.
Chamoto K; Wakita D; Ohkuri T; Uchinami Y; Matsushima K; Kitamura H; Nishimura T
Cancer Sci; 2010 Apr; 101(4):855-61. PubMed ID: 20151983
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
[TBL] [Abstract][Full Text] [Related]
10. T regulatory cells in cancer: recent advances and therapeutic potential.
Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.
Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH
J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
[TBL] [Abstract][Full Text] [Related]
13. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
[TBL] [Abstract][Full Text] [Related]
14. Functional changes in myeloid-derived suppressor cells (MDSCs) during tumor growth: FKBP51 contributes to the regulation of the immunosuppressive function of MDSCs.
Kim YS; Kim YJ; Lee JM; Kim EK; Park YJ; Choe SK; Ko HJ; Kang CY
J Immunol; 2012 May; 188(9):4226-34. PubMed ID: 22474024
[TBL] [Abstract][Full Text] [Related]
15. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
[TBL] [Abstract][Full Text] [Related]
16. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
[TBL] [Abstract][Full Text] [Related]
17. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas.
Fujimura T; Ring S; Umansky V; Mahnke K; Enk AH
J Invest Dermatol; 2012 Apr; 132(4):1239-46. PubMed ID: 22189788
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
20. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
